| 000 | 01161 a2200337 4500 | ||
|---|---|---|---|
| 005 | 20250514034021.0 | ||
| 264 | 0 | _c20020712 | |
| 008 | 200207s 0 0 eng d | ||
| 022 | _a0140-6736 | ||
| 024 | 7 |
_a10.1016/S0140-6736(02)08496-9 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aWarren, Robin M | |
| 245 | 0 | 0 |
_aHIV-1 and tuberculosis infection. _h[electronic resource] |
| 260 |
_bLancet (London, England) _cMay 2002 |
||
| 300 |
_a1618-9; author reply 1619-20 p. _bdigital |
||
| 500 | _aPublication Type: Comment; Letter | ||
| 650 | 0 | 4 |
_aAntitubercular Agents _xtherapeutic use |
| 650 | 0 | 4 | _aHIV Seronegativity |
| 650 | 0 | 4 | _aHIV Seropositivity |
| 650 | 0 | 4 |
_aHIV-1 _ximmunology |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aMining |
| 650 | 0 | 4 | _aOccupational Exposure |
| 650 | 0 | 4 | _aRecurrence |
| 650 | 0 | 4 | _aRisk Factors |
| 650 | 0 | 4 |
_aSouth Africa _xepidemiology |
| 650 | 0 | 4 |
_aTuberculosis, Pulmonary _xdrug therapy |
| 700 | 1 | _avan Helden, Paul D | |
| 773 | 0 |
_tLancet (London, England) _gvol. 359 _gno. 9317 _gp. 1618-9; author reply 1619-20 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1016/S0140-6736(02)08496-9 _zAvailable from publisher's website |
| 999 |
_c11944391 _d11944391 |
||